C reactive protein testing Market Research Report: Information By Assay Type (Enzyme-linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays, and Others), By Application (Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global C-Reactive protein testing Market Overview

C reactive protein testing Market Size was valued at USD 2.9 Billion in 2022 and is projected to grow from USD 2.99 Billion in 2023 to USD 3.82 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.90% during the forecast period (2023 - 2032). Increasing elderly population and need for healthcare services globally are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

C-Reactive protein testing Market Trends

• Growing in chronic illnesses is driving the market growth

Market CAGR for C reactive protein testing is being driven by the rising chronic illnesses. The rising frequency of endometriosis in women worldwide, the rise in chronic illnesses such as inflammatory disorders, rheumatoid arthritis, and cardiovascular disease, and the growing need for healthcare services. For instance, 20.1 million persons aged 20 and older had coronary artery disease (CAD) in 2021, according to statistics released by the Centres for Disease Control and Prevention (CDC) and updated in October 2022. Additionally, it has been stated that about 805,000 Americans get a heart attack each year. Increased CRP testing used to assess cardiovascular disease risk results from a rise in the prevalence of cardiovascular illnesses, fueling market expansion. The development of portable bioanalytical tests with high specificity and sensitivity, quick reaction times, and multiplexing capabilities for on-site precise disease diagnosis and monitoring are also anticipated to benefit from improvements in nanotechnological techniques. Throughout the projection period, these developments are anticipated to increase demand for CRP testing. The primary drivers of the C-reactive Protein Testing market are the rising prevalence of cardiovascular disorders worldwide and research & development to modernize the C-reactive Protein Testing techniques. According to a study done in 2019 by the American Heart Association (AHA), cardiovascular disorders cause more than 801,000 deaths in the US and about 2,200 patient fatalities.

An aging population and a rise in diabetes mellitus incidence are also driving the market for C-reactive Protein Testing. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry. Gastrointestinal illnesses and the associated demand for effective disease testing techniques have driven the industry. Adult patients with a diagnosis of a respiratory tract infection should undergo POC CRP testing in primary care, according to the National Institute of Health and Care Excellence. The industry is being driven by initiatives done by government organizations to raise awareness and adoption of point of care. An increase in funding and investments for organizations doing research operations in the field and a boost for market expansion. The top cause of mortality globally, according to the World Heart Federation, is coronary heart disease. According to estimates, coronary heart disease claims the lives of 3.4 million women and 3.8 million men annually. Due to their diverse optical characteristics, plasmonic nanoparticles (PNPs) are one of the technologies that may be employed for biosensing applications.. Thus, driving the C reactive protein testing market revenue.

C-Reactive protein testing Market Segment Insights

C-Reactive protein testing Assay Type Insights

 Based on type, the market segments of C reactive protein testing includes enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), immunoturbidimetric assays, and others. The enzyme-linked immunosorbent assay (ELISA) segment dominated the market, accounting for 35% of market revenue. The rise in the market is ascribed to ELISA's many advantages, including the fact that it is an easy, fast, accurate, and reliable analytical technique for identifying and measuring human C-reactive protein in the blood. The development of this market is also significantly influenced by the rise in the incidence of chronic and infectious illnesses, the rise in the geriatric population, the surge in product releases, and collaborations with other market participants for the marketing of ELISA tests.

C reactive protein testing Application Insights

The C-Reactive protein testing market segmentation, based on Application, includes diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, and others. The cardiovascular disease category generated the most income. The increase in the prevalence of CVDs is the main factor driving market development. A sedentary lifestyle, hypertension, obesity, and diabetes are a few risk factors for CVDs. C-reactive protein is the noninvasive biomarker for inflammation in CVDs that has been most fully studied, and there are currently several hs-CRP assays available.

Figure 1: C reactive protein testing Market, by Application, 2022 & 2032 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

 C reactive protein testing Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American C-Reactive protein testing market will dominate this market, with an increase in the adoption of cutting-edge technology and a significant focus on clinical research in North America. Given how prevalent cancer is in the United States, CRP testing is often employed.

Further, the major countries studied in the market report are The US, Canada, German, Italy, Spain, China, Japan, France, the UK, India, Australia, South Korea, and Brazil.

Figure 2: C REACTIVE PROTEIN TESTING MARKET SHARE BY REGION 2022 (USD Billion) 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe has the second-largest market share for C-reactive protein testing. The prevalence of a well-established healthcare infrastructure, rising rates of CVD, rheumatoid arthritis, and other inflammatory diseases, and a favorable reimbursement environment. Furthermore, the German market of C reactive protein testing dominated, while the UK market of C reactive protein testing grew fastest in Europe.

From 2023 to 2032, the Asia-Pacific C reactive protein testing Market will develop at the quickest CAGR. An increase in hospitals and a rise in hospital admissions for emergency treatment are driving the market's expansion in this area. A key factor driving market development is the rise in traffic accidents, which raises the patient population. Furthermore, China's market of C reactive protein testing had the highest market share. In contrast, the Asia-Pacific region's market of C reactive protein testing in India was the one that was growing the quickest.

C reactive protein testing Key Market Players & Competitive Insights

Leading market companies are extensively spending R&D on increasing their product lines, which will help the market of C reactive protein testing grow even more. Important market developments include new product releases, contractual agreements, acquisitions and mergers, greater investments, and collaboration with other organizations. The C reactive protein testing industry must produce cost-effective merchandise to flourish and thrive in a more competitive and increasing market climate.

Manufacturing locally to reduce operating costs is an effective business strategy manufacturers use in the worldwide C reactive protein testing industry to serve clients and expand the market sector. The C reactive protein testing industry has provided some of the most important benefits recently. LumiraDx, Trivitron Healthcare's, and other major competitors in the market of C reactive protein testing are seeking to improve market demand by investing in R&D efforts.

A next-generation point-of-care diagnostics business called LumiraDx is revolutionizing community-based healthcare. Since its establishment in 2014, LumiraDx has produced and sold a revolutionary diagnostic Platform that enables a wide range of tests with point-of-care performance that is on par with a lab's. Governments and top healthcare organizations use LumiraDx diagnostic testing systems in clinics, urgent care centers, doctor's offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness and illness. On the LumiraDx Platform, LumiraDx offers more than 30 tests for infectious illnesses, cardiovascular diseases, diabetes, and coagulation disorders available or under development. Additionally, LumiraDx offers a wide range of quick, precise, and reasonably priced COVID-19 testing options from the lab to the point of need. In January 2022, LumiraDx announced the C-reactive protein (CRP) Test CE Marking. The LumiraDx CRP Test measures C-reactive protein quantitatively and provides findings in four minutes. It is a tiny, portable, fully automated microfluidic immunoassay test. CRP testing offers crucial information to diagnose and assess infection and inflammation.

Trivitron Healthcare's history as a medical technology firm offering cost-effective solutions has been a fascinating source of inspiration for many healthcare professionals since 1997. Hospitals, private healthcare practitioners, independent clinics and laboratories, long-term care facilities, renal care centers, and other structures offering healthcare solutions are the target markets for Trivitron's goods. Trivitron, a leader in the industry, is continually looking for new technical advancements to provide better clinical advantages at a reduced price. In June 2021, In order to simplify COVID-19 diagnosis in remote, urban, and rural areas of India, Trivitron Healthcare created a mobile laboratory. The local lab offers RT-PCR assays, fast antigen tests, CLIA/Elisa IgG and IgM antibody tests, and CLIA/Elisa tests for inflammatory indicators, including D-Dimer, CRP and IL-6.

Key Companies in the market of C reactive protein testing include

• 
  

  Randox Laboratories Limited

  
  


• 
  

  Merck KGAA (Millipore Sigma)

  
  


• 
  

  Quest Diagnostics Incorporated

  
  


• 
  

  Abbott Laboratories

  
  


• 
  

  Zoetis Inc. (Abaxis Inc.)

  
  


• 
  

  Thermo Fisher Scientific, Inc.

  
  


• 
  

  Danaher Corporation (Beckman Coulter Inc.)

  
  


• 
  

  Horiba, Ltd.

  
  


• 
  

  Laboratory Corporation of America Holdings

  
  


• 
  

  F. Hoffmann-La Roche AG.

  
  

C reactive protein testing Industry Developments

November 2022:The FDA has approved the ProciseDx instrument and CRP test, according to ProciseDx Inc. In less than 5 minutes, Procise CRP quantitatively assesses CRP levels in patient serum. In 2023, ProciseDx anticipates receiving FDA approval for further testing.

July 2022:The C-Reactive Protein (CRP) in the circulation is measured and detected using the Bloom Inflammation Test, developed by Swiss medical technology firm Bloom Diagnostics.

January 2022:The C-reactive protein PCR test from LumiraDx has received CE mark certification. It is a small, portable, fully automated microfluidic immunoassay test with a four-minute turnaround time for quantitatively detecting C-reactive protein.

C reactive protein testing Market Segmentation

C reactive protein testing Assay Type Outlook

• 
  

  Enzyme-linked immunosorbent assay (ELISA)

  
  


• 
  

  Chemiluminescence Immunoassay (CLIA)

  
  


• 
  

  Immunoturbidimetric assays

  
  


• 
  

  Others

  
  

C reactive protein testing Application Outlook

• 
  

  Diabetes

  
  


• 
  

  Rheumatoid Arthritis

  
  


• 
  

  Cardiovascular Disease

  
  


• 
  

  Inflammatory Bowel Disease

  
  


• 
  

  Others

  
  

C reactive protein testing Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America